News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Are CNTA, KORE, CWAN Obtaining Fair Deals for their Shareholders?

Centessa Pharmaceuticals (CNTA) had its "equal weight" rating reaffirmed by Wells Fargo & Company. They now have a $42.00 price target on the stock, up from $35.00.

Centessa Pharmaceuticals (CNTA) was downgraded by Truist Financial Corporation from "buy" to "hold". They now have a $38.00 price target on the stock.

Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders

Centessa Pharmaceuticals (CNTA) had its "neutral" rating reaffirmed by Guggenheim.

3/31/2026

04:31 pm

CNTA

0.5%

MISS

8/12/2025

07:00 am

CNTA

-4.7%

MISS

5/14/2025

07:00 am

CNTA

-1.1%

BEAT

Wells Fargo & Company

Form PREM14A Centessa Pharmaceuticals For: Apr 17

Form DEFA14A Centessa Pharmaceuticals

Form DEFA14A Centessa Pharmaceuticals

Form DEFA14A Centessa Pharmaceuticals

Form DEFA14A Centessa Pharmaceuticals

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}